AG-exclusion zone revisited: Lessons to learn from 91 intronic NF1 3' splice site mutations outside the canonical AG-dinucleotides.


Journal

Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429

Informations de publication

Date de publication:
06 2020
Historique:
received: 25 09 2019
revised: 26 01 2020
accepted: 24 02 2020
pubmed: 4 3 2020
medline: 6 11 2021
entrez: 4 3 2020
Statut: ppublish

Résumé

Uncovering frequent motives of action by which variants impair 3' splice site (3'ss) recognition and selection is essential to improve our understanding of this complex process. Through several mini-gene experiments, we demonstrate that the pyrimidine (Y) to purine (R) transversion NM_000267.3(NF1):c.1722-11T>G, although expected to weaken the polypyrimidine tract, causes exon skipping primarily by introducing a novel AG in the AG-exclusion zone (AGEZ) between the authentic 3'ss AG and the branch point. Evaluation of 90 additional noncanonical intronic NF1 3'ss mutations confirmed that 63% of all mutations and 89% (49/55) of the single-nucleotide variants upstream of positions -3 interrupt the AGEZ. Of these AGEZ-interrupting mutations, 24/49 lead to exon skipping suggesting that absence of AG in this region is necessary for accurate 3'ss selection already in the initial steps of splicing. The analysis of 91 noncanonical NF1 3'ss mutations also shows that 90% either introduce a novel AG in the AGEZ, cause a Y>R transversion at position -3 or remove ≥2 Ys in the AGEZ. We confirm in a validation cohort that these three motives distinguish spliceogenic from splice-neutral variants with 85% accuracy and, therefore, are generally applicable to select among variants of unknown significance those likely to affect splicing.

Identifiants

pubmed: 32126153
doi: 10.1002/humu.24005
pmc: PMC7317903
doi:

Substances chimiques

NF1 protein, human 0
Neurofibromin 1 0
RNA Splice Sites 0
Ribonucleoproteins, Small Nuclear 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1145-1156

Informations de copyright

© 2020 The Authors. Human Mutation published by Wiley Periodicals, Inc.

Références

Hum Mol Genet. 1998 May;7(5):919-32
pubmed: 9536098
Nucleic Acids Res. 2006;34(16):4630-41
pubmed: 16963498
Science. 1997 Jun 13;276(5319):1712-6
pubmed: 9180084
Cell. 1985 Oct;42(3):725-36
pubmed: 2996774
J Mol Biol. 2001 Apr 13;307(5):1261-70
pubmed: 11292340
Hum Genomics. 2009 Dec;4(2):69-72
pubmed: 20038494
Hum Mutat. 2011 Jul;32(7):705-9
pubmed: 21394830
Nat Rev Genet. 2002 Apr;3(4):285-98
pubmed: 11967553
BMC Biol. 2016 Jul 05;14:54
pubmed: 27380775
Nat Rev Genet. 2007 Oct;8(10):749-61
pubmed: 17726481
Hum Mol Genet. 2000 Jan 22;9(2):237-47
pubmed: 10607834
Mol Cell Biol. 1996 Aug;16(8):4014-23
pubmed: 8754799
Hum Mutat. 2020 Jun;41(6):1145-1156
pubmed: 32126153
Hum Mutat. 2012 Aug;33(8):1228-38
pubmed: 22505045
Nucleic Acids Res. 1987 Sep 11;15(17):7155-74
pubmed: 3658675
Hum Mutat. 2007 Jun;28(6):599-612
pubmed: 17311297
J Comput Biol. 2004;11(2-3):377-94
pubmed: 15285897
RNA. 1995 Nov;1(9):869-85
pubmed: 8548652
Cell. 2009 Feb 20;136(4):701-18
pubmed: 19239890
Mol Cell Biol. 2001 Mar;21(5):1509-14
pubmed: 11238888
Nucleic Acids Res. 2001 Mar 1;29(5):1185-90
pubmed: 11222768
J Comput Biol. 1997 Fall;4(3):311-23
pubmed: 9278062
Nucleic Acids Res. 2017 Feb 28;45(4):2051-2067
pubmed: 27683217
Nucleic Acids Res. 2018 Sep 6;46(15):7913-7923
pubmed: 29750258
Genome Biol. 2006;7(1):R1
pubmed: 16507133
Nucleic Acids Res. 2009 May;37(9):e67
pubmed: 19339519
Hum Mutat. 2000;15(6):541-55
pubmed: 10862084
Clin Sci (Lond). 2017 Mar 1;131(5):355-368
pubmed: 28202748

Auteurs

Katharina Wimmer (K)

Institute of Human Genetics, Department of Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.

Esther Schamschula (E)

Institute of Human Genetics, Department of Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.

Annekatrin Wernstedt (A)

Institute of Human Genetics, Department of Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.

Pia Traunfellner (P)

Institute of Human Genetics, Department of Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.

Albert Amberger (A)

Institute of Human Genetics, Department of Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.

Johannes Zschocke (J)

Institute of Human Genetics, Department of Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.

Peter Kroisel (P)

Diagnostic & Research Institute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.

Yunjia Chen (Y)

Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama.

Tom Callens (T)

Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama.

Ludwine Messiaen (L)

Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH